Aktienanalyse wird geladen …
VRTX · NASDAQ · Pharmaceuticals · USA
522,33 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 12 Mrd. | 3,95 Mrd. | 15,32 $ | 258 Mio. | 1,3 Mio · 0,5 % | — | 86,2 % | 32,9 % | 12,38 $ | 2,66 $ | — |
| 2024 | 11,02 Mrd. | -535,6 Mio. | -2,08 $ | 257,9 Mio. | 1,3 Mio · 0,5 % | — | 86,1 % | -4,9 % | -3,06 $ | 2,71 $ | — |
| 2023 | 9,87 Mrd. | 3,62 Mrd. | 13,89 $ | 260,5 Mio. | 1,1 Mio · 0,4 % | — | 87,2 % | 36,7 % | 12,81 $ | 2,23 $ | — |
| 2022 | 8,93 Mrd. | 3,32 Mrd. | 12,82 $ | 259,1 Mio. | 0,9 Mio · 0,4 % | 1,7 Mio · 0,7 % | 87,9 % | 37,2 % | 15,15 $ | 1,90 $ | — |
| 2021 | 7,57 Mrd. | 2,34 Mrd. | 9,01 $ | 259,9 Mio. | 0,8 Mio · 0,3 % | 4,3 Mio · 1,7 % | 88,1 % | 30,9 % | 9,27 $ | 1,70 $ | — |
| 2020 | 6,21 Mrd. | 2,71 Mrd. | 10,29 $ | 263,4 Mio. | 0,8 Mio · 0,3 % | — | 88,1 % | 43,7 % | 11,37 $ | 1,63 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,33 Mrd. | 1,1 Mrd. | 4,31 $ | 255,2 Mio. | 33 % | 3,97 $ |
| Q1 2026 | 2,99 Mrd. | 1,03 Mrd. | 4,02 $ | 256,3 Mio. | 34,5 % | 5,05 $ |
| Q4 2025 | 3,19 Mrd. | 1,19 Mrd. | 4,62 $ | 256,1 Mio. | 37,3 % | 1,35 $ |
| Q3 2025 | 3,08 Mrd. | 1,08 Mrd. | 4,20 $ | 257,6 Mio. | 35,2 % | 4,42 $ |
| Q2 2025 | 2,96 Mrd. | 1,03 Mrd. | 3,99 $ | 258,9 Mio. | 34,8 % | 3,58 $ |
| Q1 2025 | 2,77 Mrd. | 646,3 Mio. | 2,49 $ | 259,5 Mio. | 23,3 % | 3,00 $ |
| Q4 2024 | 2,91 Mrd. | 913 Mio. | 3,54 $ | — | 31,4 % | 1,91 $ |
| Q3 2024 | 2,77 Mrd. | 1,05 Mrd. | 4,01 $ | 261 Mio. | 37,7 % | 4,99 $ |
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX. Vertex serves patients across the United States, Europe, and other international markets, with a business model that combines specialized research, regulatory development, manufacturing, and commercialization capabilities. The company is known for operating in highly scientific and tightly regulated therapeutic markets, where innovation, clinical expertise, and product execution are central to its role. Vertex Pharmaceuticals Incorporated Common Stock is used by investors to track and participate in the performance of a biotechnology business with a strong presence in specialty pharmaceuticals and advanced medicine development.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest VRTX und jede andere Aktie unbegrenzt.